Tempus AI, a leader in artificial intelligence and precision medicine, announced a new collaboration for pulmonary hypertension (PH) with United Therapeutics (UT), a leading biotechnology company focused on developing novel pharmaceuticals and technologies. This partnership aims to create and investigate AI-based medical device software to detect patients at risk of undiagnosed pulmonary hypertension, a serious and often fatal condition.
Pulmonary hypertension is a progressive disease of the heart and lungs that affects approximately 1% of the population. Despite advancements in available treatments, the detection or clinical diagnosis of PH is typically delayed for two or more years, which significantly impacts patient outcomes. To address this critical issue, Tempus has developed an algorithm that automatically analyzes the results of a 12-lead electrocardiogram (ECG) to identify patients at risk of undiagnosed pulmonary hypertension for further clinical evaluation. The initial findings from this innovative work were recently presented at the American Thoracic Society International Conference in San Diego, California, on May 22, 2024.
Tempus’ research and development program will leverage Tempus Next, the company’s AI-enabled care pathway intelligence solution, to facilitate the deployment of the algorithm at participating centers. Clinicians will evaluate its ability to detect patients at risk of undiagnosed PH and track the clinical outcomes of patients who are identified for further evaluation within a prospective clinical study at up to 60 centers. This comprehensive study aims to investigate the clinical impact of this technology and gain new insights into the detection and diagnosis of pulmonary hypertension.
Tempus and United Therapeutics Partner with FDA to Advance AI in Pulmonary Hypertension Diagnosis
As part of this collaboration, Tempus and United Therapeutics plan to engage with the Food and Drug Administration (FDA) to align on regulatory requirements and FDA expectations regarding the validation of this novel AI-based algorithm. The collaboration seeks to establish a new standard in identifying patients with pulmonary hypertension by utilizing cutting-edge technology to enable earlier diagnosis and more effective disease management.
“We aim to set a new standard for identifying patients with pulmonary hypertension by getting novel technology into the hands of clinicians to enable earlier diagnosis and more effective disease management,” said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. “Exploring this in a prospective multicenter study brings us one step closer to realizing the dream of data-driven precision medicine.”
Tempus is committed to leveraging its extensive multimodal data library to enhance diagnostic accuracy and patient care. The company’s AI-driven solutions are designed to support physicians in making more informed decisions, ultimately improving the quality of care for patients at risk of pulmonary hypertension and other cardiovascular conditions. By integrating AI with clinical practice, Tempus aims to transform the landscape of cardiovascular disease diagnosis and management.
Tempus Advances Precision Medicine with AI, Enhances Cardiovascular Care
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians, facilitating personalized patient care. In parallel, Tempus aids in the discovery, development, and delivery of optimal therapeutics. The goal is to ensure that each patient benefits from the treatments of others who came before by equipping physicians with tools that continuously learn and improve as more data is gathered.
“We are excited about the potential impact of our collaboration with United Therapeutics,” added Fornwalt. “Our goal is to empower clinicians with the tools they need to make more informed decisions, ultimately improving the quality of care for patients at risk of PH and other cardiovascular conditions.”
In conclusion, the collaboration between Tempus and United Therapeutics represents a significant advancement in the use of AI for cardiovascular care. It not only validates the effectiveness of the algorithm but also paves the way for its integration into clinical practice, potentially transforming the way pulmonary hypertension is diagnosed and managed. Tempus remains at the forefront of precision medicine, committed to leveraging AI to provide actionable insights that enhance patient care and outcomes. This partnership highlights the potential of AI-driven solutions in revolutionizing healthcare and underscores the importance of innovative approaches in addressing critical health challenges.
Resource: Tempus, June 25, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
